ArticleFrontiers in microbiology2025
Gut microbiome modulation by Weifuchun Capsules alleviates chronic atrophic gastritis: a combined microbiota and metabolomics approach.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transforming Gastric Biopsy Diagnostics: Integrating Omics Technologies and Artificial Intelligence.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Weifuchun Capsule (WFC), a traditional Chinese medicinal formula containing Methods: We established a rat model of CAG to investigate the microbiota-associated mechanisms underlying the effects of WFC treatment. Integrated microbiome-metabolome analyses were performed, combining 16S rRNA gene sequencing for gut microbiota profiling and untargeted metabolomics to detect shifts in metabolic pathways. Network pharmacology identified bioactive compounds from 99 characterized components in WFC, with molecular docking analyses further validating these findings. Correlations between gut microbial composition and metabolic profiles were assessed using Spearman's analysis, and western blotting was employed to evaluate inflammation-associated proteins. Results: Network pharmacology screening identified 10 bioactive components from the 99 constituents present in WFC. Treatment with WFC significantly restored gut microbiota diversity and composition in CAG rats, notably enriching four bacterial families and ten genera. Metabolomic profiling revealed substantial regulation of glycerophospholipid and arachidonic acid metabolism, pathways intricately linked to microbial activity and gastrointestinal inflammation. Conclusion: Our findings highlight that modulation of gut microbiota composition is central to the therapeutic effects of WFC on CAG. WFC exerts its gastroprotective activity primarily by reshaping specific gut microbial populations and subsequently normalizing associated metabolic pathways. This microbiome-oriented perspective provides new insights into traditional herbal medicine mechanisms, emphasizing the critical need to understand microbiota-mediated therapeutic strategies in gastrointestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.